Status:
UNKNOWN
Autoimmunity in Patients With GAD-Ab and Their Relatives
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Neurological Syndromes With GAD-Ab
Organ-specific Autoimmune Diseases
Eligibility:
All Genders
18+ years
Brief Summary
A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma...
Detailed Description
A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma...
Eligibility Criteria
Inclusion
- Patient with a well-known neurological syndrome associated with Gad-Ab (LE, CA, SPS)
- Patient with an CSF positive for GAD-Ab;
- Patient witn an Age \> 18 years old.
Exclusion
- Patient with absence of complete clinical data.
- Patient with CSF not tested or negative for GAD-Ab
Key Trial Info
Start Date :
September 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04104620
Start Date
September 30 2019
End Date
September 30 2020
Last Update
September 27 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.